



3753
RLL-248US *END*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: RAMPAL et al.

Serial No.: 10/509,704

Filing Date: September 30, 2004

Title: CLARITHROMYCIN FORMULATIONS HAVING IMPROVED
BIOAVAILABILITY

CERTIFICATE OF MAILING

I certify that the following correspondence:

- Transmittal of Information Disclosure Statement
- Information Disclosure Citation w/references
- Postcard

is being deposited on May ~~20~~, 2005 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Susan Dolci
Susan Dolci

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-248US

In Re Application Of: RAMPAL et al.

MAY 23 2005

PATENT & TRADEMARK

Application No.	Filing Date	Examiner	Customer No.	Group Art Unit	Confirmation No.
10/509,704	09/30/2004	TBA	26815	3753	7758

Title:

CLARITHROMYCIN FORMULATIONS HAVING IMPROVED BIOAVAILABILITY

Address to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

37 CFR 1.97(b)

1. ☒ The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

37 CFR 1.97(c)

2. ☐ The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:

☐ the statement specified in 37 CFR 1.97(e);


OR

☐ the fee set forth in 37 CFR 1.17(p).

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT
(Under 37 CFR 1.97(b) or 1.97(c))

Docket No.
RLL-248US

In Re Application: **RAMPAL et al.**



Application No. 10/509,704	Filing Date 09/30/2004	Examiner TBA	Customer No. 26815	Group Art Unit 3753	Confirmation No. 7758
--------------------------------------	----------------------------------	------------------------	------------------------------	-------------------------------	---------------------------------

Title:

CLARITHROMYCIN FORMULATIONS HAVING IMPROVED BIOAVAILABILITY

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☒ The Director is hereby authorized to charge and credit Deposit Account No. **50-0912** as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☒ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)	
(Date)	_____
Signature	_____
Typed or Printed Name of Person Signing Certificate	

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____	
May 20, 2005	_____
(Date)	_____
Signature	<i>Susan Dolci</i>
Signature of Person Mailing Correspondence	
Susan Dolci	
Typed or Printed Name of Person Mailing Certificate	

*This certificate may only be used if paying by deposit account.

William D. Hare
Signature

Dated: May 20, 2005

William D. Hare, Esq.
Reg. No. 44,739
Ranbaxy Inc.
600 College Road East, Suite 2100
Princeton, NJ 08540
Tel. 609 720-5378
Fax 609 514-9779

CC:

INFORMATION DISCLOSURE CITATION


Docket No.: RLL-248US

Serial No.: 10/509,704

Applicants: RAMPAL *et al.*

Filed: 9/30/2004

Group:



U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A1	4,331,803	5/25/1982	Watanabe <i>et al.</i>	536	7.2	
	A2	4,672,109	6/9/1987	Watanabe <i>et al.</i>	536	7.2	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO	
	B1	WO 00/48607	8/24/2000	PCT	A61K	31/70		
	B2	WO 02/17885	3/7/2002	PCT	A61K	9/20		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	C1	Database WPI. Section Ch, Week 199720. Derwent Publications Ltd., London, GB; Class A96, AN 1997-221685. XP002254913 & JP 09 067247 A (Taisho Pharm. Co. Ltd.), 11 March 1997 abstract
	C2	Database WPI. Section Ch, Week 199344. Derwent Publications Ltd., London, GB; Class A96, AN 1993-348367. XP002254914 & JP 05 255120 A (Taisho Pharm. Co. Ltd.), 5 October 1993 abstract
	C3	Rasenack and Müller, "Mikro- und Nanoteilchen Die Bedeutung der Teilchengröße in der Pharmazie", <i>PZ Prisma, Vi Verlag, Eschborn, Go</i> , 9(3):183-190 (2002) XP008021338 ISSN: 0945-5566

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.